Onconeural Antibodies in Metastatic Renal Cell Carcinoma: A Hypothesis-Generating Study of Anti-Hu Antibodies and Overall Survival
Antibodies · 06.11.2026 · 15 (6) · 106
DOI: 10.3390/antib15060106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibodies, online erschienen am 06.11.2026. Verfasst von Edina Kovács und 7 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Onconeural antigens expressed by tumor cells may trigger the production of onconeural antibodies, which result in paraneoplastic neurological syndromes (PNS).
Objectives
We investigated the presence of eight onconeural antibodies (amphiphysin, CRMP5, Nova/Ri, Cdr2/Yo, Elav/Hu, Zic4, Ma2, recoverin) and neurologic symptoms and signs in 33 metastatic renal cell carcinoma patients who started first-line therapy. Overall survival (OS) and time to treatment failure (TTF) were also determined.
Methods
Sera were tested on a dot blot of purified, recombinant, human onconeural antigens. Neurologic symptoms were reviewed by a questionnaire, and signs were determined by a dedicated neurologist. OS and TTF of patients were determined by Kaplan–Meier analysis.
Results
51% of patients (17 of 33) harbored at least one onconeural antibody, 36% of patients had multiple antibodies. Two patients with cerebellar signs and three patients with signs of polyneuropathy had onconeural antibodies, suggesting a definite PNS. Six additional patients with polyneuropathy and without onconeural antibodies might have possible PNS. OS was significantly longer in patients harboring the anti-Hu antibody (n = 14) compared to those without it (n = 19) (median survival was 745 and 135 weeks, respectively).
Conclusions
We have found that the occurrence of onconeural antibodies is relatively high in metastatic RCC, not reported previously. A significant percentage of these patients have neurological symptoms with a probable paraneoplastic background, which may have a detrimental impact on their quality of life. Anti-Hu antibody was identified most frequently. Our preliminary data show that the presence of anti-Hu antibody correlates with better prognosis and survival, suggesting the beneficial role of activated autoimmunity. In the era of frontline immune checkpoint inhibitor (ICI) therapy of RCC, it would be strongly encouraged to further explore the prognostic and potentially predictive role of anti-Hu antibody.
Zitieren
APA
Kovács, E., Kozák, M., Balogh, I., Kocsis, J., Horváth, Z., Kádár, Á. M., Tóth, A., & Boczán, J. (2026). Onconeural Antibodies in Metastatic Renal Cell Carcinoma: A Hypothesis-Generating Study of Anti-Hu Antibodies and Overall Survival. Antibodies, 15(6), 106. https://doi.org/10.3390/antib15060106
Vancouver
Kovács E, Kozák M, Balogh I, Kocsis J, Horváth Z, Kádár ÁM, et al. Onconeural Antibodies in Metastatic Renal Cell Carcinoma: A Hypothesis-Generating Study of Anti-Hu Antibodies and Overall Survival. Antibodies. 2026;15(6):106. doi:10.3390/antib15060106
BibTeX
@article{Kovcs2026,
author = {Kovács, Edina and Kozák, Márk and Balogh, Ingrid and Kocsis, Judit and Horváth, Zsolt and Kádár, Álmos Márk and Tóth, Attila and Boczán, Judit},
title = {Onconeural Antibodies in Metastatic Renal Cell Carcinoma: A Hypothesis-Generating Study of Anti-Hu Antibodies and Overall Survival},
journal = {Antibodies},
year = {2026},
volume = {15},
number = {6},
pages = {106},
doi = {10.3390/antib15060106}
}
EUVIMED